At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,180 enrolled
Drug / intervention
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%, Acanya Gel, and 1 other intervention for Acne. Completed, enrolled 1,180 participants.
Detailed Summary
The objective of this study was to evaluate the efficacy and safety of Perrigo's test formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to the already marketed formulation, Acanya gel in patients with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
Primary CompletionFeb 2013
First PostedFeb 2013
TodayJul 2026
First PostedFeb 22, 2013
Enrollment StartFeb 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.4 years ago
Interventions
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%drug
Acanya Geldrug
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% productdrug